Cannabinoids found to reduce seizures in children with epilepsy

(Natural News) The use of medical marijuana is starting to gain more acceptance throughout the U.S., and researchers are constantly uncovering new benefits. One recent analysis shows just how promising it could be when it comes to addressing a challenging condition in children: epilepsy. Epilepsy is more common in children than you might think, with...
Source: - Category: Consumer Health News Source Type: news

Related Links:

Review ArticlesAndrea E. Cavanna, Stefano Seri,Acta Neuropsychiatrica,Volume 28 Issue 04, pp 185-194Abstract
Source: Acta Neuropsychiatrica - Category: Neurology Source Type: research
Sara Sambin, Nicolas Gaspard, Benjamin Legros, Chantal Depondt, Sandra De Breucker, Gilles Naeije
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study explored the perceptions of healthcare providers in the Irish epilepsy care ecosystem to understand their level of readiness to realize the benefits of an integrated PCC model. Ethnographic fieldwork including observations of different clinical settings across three regions in Ireland and one-to-one interviews with consultant epileptologists (n = 3), epilepsy specialist nurses (n = 5), general practitioners (n = 4), and senior healthcare managers (n = 3) were conducted. While there is a person-centered ambiance and a disposition toward advancing integrated PCC, there are limits to the readiness o...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
ConclusionsPerampanel is effective against various types of seizures, including ES, in pediatric patients with refractory epilepsy. Furthermore, PER has good tolerability when the dose is adjusted based on serum concentrations. The PER CD ratio was lower in pediatric patients than in adolescents and adults; therefore, clinicians must consider the CD ratio when treating children with PER.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
Publication date: Available online 18 March 2019Source: Epilepsy &BehaviorAuthor(s): Gia Melikishvili, Nino Epitashvili, Nazi Tabatadze, Gocha Chikvinidze, Olivier Dulac, Thierry Bienvenu, Svetlana GataullinaAbstractEight patients, seven girls and one boy, had CDKL5 gene mutation, duplication, or deletion. Epileptic spasms started at a mean age of 3.5 months (range = 4 weeks–8 months). In five cases, tonic seizures preceded spasms at a median age of 6 weeks. In one patient who started at 8 months, spasms had a component of terror on awakening, reminding sleep terror. In two patients, electroencephal...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
Publication date: Available online 18 March 2019Source: Epilepsy &BehaviorAuthor(s): Rosemarie Kobau, Sanjeeb Sapkota, Matthew M. ZackAbstractSerious psychological distress (SPD) includes mental health problems severe enough to cause moderate-to-serious impairment in daily activities and to require treatment. Serious psychological distress is based on answers to six survey questions from the Kessler-6 scale used internationally in public health surveillance systems to assess recent feelings of sadness, restlessness, hopelessness, nervousness, worthlessness, and the sense that everything is an effort. We combined nation...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
Abstract: Epilepsy is characterized by seizures recurring at interindividually differing time intervals. It may be difficult to assess drug response if time intervals between seizures are long. Thus, the existence of surrogate parameters that could be used to reliably identify drug efficacy and tolerability at an early stage and also as prognostic factors would be desirable. Electroencephalography, magnetic resonance imaging, and genetic markers are the domains to be assessed in this respect. The availability of clinically useful pharmacodynamic parameters is, however, currently disappointing.
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Review Articles: Focus on Pharmacodynamic Drug Monitoring Source Type: research
Authors: Rheims S, Dupont S, Derambure P PMID: 30879489 [PubMed - in process]
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Vagus nerve stimulation (VNS) was the first neuromodulation device approved for treatment of epilepsy. In more than 20  years of study, VNS has consistently demonstrated efficacy in treating epilepsy. After 2 years, approximately 50% of patients experience at least 50% reduced seizure frequency. Adverse events with VNS treatment are rare and include surgical adverse events (including infection, vocal cord paresis, and so forth) and stimulation side effects (hoarseness, voice change, and cough). Future developments in VNS, including closed-loop and noninvasive stimulation, may reduce side effects or increase efficacy of VNS.
Source: Neurosurgery Clinics of North America - Category: Neurosurgery Authors: Source Type: research
By analyzing the white-matter connections of an infant's brain at birth on...Read more on AuntMinnie.comRelated Reading: PET, AI show women's brains age differently than men's Machine learning, fMRI unlock cellular brain properties AI, diffusion MRI can predict outcomes for epilepsy AI helps uncover clues for Alzheimer's disease in MRI data NYMIIS: Next-gen PACS will include 'best-of-breed' AI
Source: Headlines - Category: Radiology Source Type: news
More News: Children | Epilepsy